Drug Profile
Research programme: inflammation therapy - Immusol/Vertex
Latest Information Update: 28 Sep 2006
Price :
$50
*
At a glance
- Originator Immusol; Vertex Pharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Inflammation
Most Recent Events
- 28 Sep 2006 Discontinued - Preclinical for Inflammation in USA (unspecified route)
- 16 Apr 2003 PanVera LLC has been acquired by Invitrogen
- 07 May 2002 Preclinical trials in Inflammation in USA (unspecified route)